Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer

Abstract

For a long time, the urological community has been on a quest to find the best means for early detection of prostate cancer (PC). An important milestone was the introduction of prostate-specific antigen (PSA)-testing. While initial results regarding a structured screening were controversial, with longer follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial [1] and more detailed assessment of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial [2,3] the advantage is increasingly evident, with the number needed to screen dropping below the levels of the widely accepted breast cancer screening [4]. A variety of markers have since been introduced with improved "sensitivity" and specificity, but low availability and high cost have prevented their wide

Micro-Ultrasound: a way to bring imaging for prostate cancer back to urology

“…Currently, mpMRI has evolved to be the gold standard in imaging of the prostate for the diagnosis of PC [ 7 , 8 , 9 , 10 ]. While studies providing a comparison of MUS and MRI are still sparse and mostly retrospective, recently published data are promising ( Table 1 ).…”

“…Here, regions of the prostate are scored from 1 (clinically significant PC [csPC] is highly unlikely to be present) to 5 (csPC is highly likely to be present). Multiple prospective studies have evaluated its role as a diagnostic tool for PC [ 7 , 8 , 9 , 10 ]. In summary, on a patient basis, the primary mpMRI has a negative predictive value (NPV) of 88% for PC and Gleason score of ≥3 + 4 [ 7 ].…”